Immunotherapy
Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial
Published in Medical Letter on the CDC and FDA, June 29th, 2008
Vical Incorporated (NASDAQ:VICL) announced the receipt of $6.3 million of cash payments and equity investments from AnGes MG, Inc., under a previously announced collaborative agreement for continued funding of the company's ongoing Allovectin-7(R) Phase 3 metastatic melanoma trial. Through a series of cash payments and equity investments, Vical has received $15.3 million to date of the $22.6 million total committed by AnGes.
Vical is conducting the Allovectin-7(R) Immunotherapeutic for Metastatic Melanoma, or AIMM trial, a Phase 3 pivotal trial of the company's Allovectin-7(R) cancer immunotherapeutic as first-line therapy in chemotherapy-naive patients with Stage III...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Norwegian Institute of Public Health
New method identifies rat poison in humans - Artes Medical, Inc.
Dermatologic Surgery Journal Publishes Comparison of Global PMMA-Based Dermal Fillers Showing Superior Characteristics of ArteFill Microspheres - Constipation
Research from College of Medicine in the area of constipation described - IntraHealth International
IntraHealth's Family Planning Work in Rwanda Contributes to Near Three-Fold Increase in Contraceptive Use in Only Three Years - Life Sciences
Data from University of Louisville advance knowledge in life sciences - Psychosis
Research results from Medical University of South Carolina update knowledge of psychosis - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
